The drug aims to reduce the sustained response, as well as reduce the rate of progression to severe COVID-19, according to Romark.

The randomized, double-blind trial will study a maximum of 800 people who are 12 and older and have fevers and respiratory symptoms consistent with COVID-19. These participants will be given either Nt-300 or a placebo twice daily for five days. Efficacy analyses will examine those participants who have laboratory-confirmed SARS-CoV-2 infection.

Romark anticipates sharing results near the end of 2020.

Novocellbio's COVID-19 cell therapy shows promising results
Novocellbio has confirmed that its autologous natural killer cell treatment agent is effective in killing SARS-CoV-2.

New COVID-19 vaccine candidate leverages earlier research
Could vaccine platforms developed for previous coronaviruses be converted to address the current COVID-19 pandemic? An August 5 report in Nature...

Celularity begins trial of COVID-19 cell therapy
Celularity has received funding to support a phase I/II clinical trial of human placental hematopoietic stem cell-derived natural killer cells for the...

J&J to provide U.S. with 100M doses of COVID-19 vaccine
Johnson & Johnson will manufacture and deliver 100 million doses of its SARS-CoV-2 investigational vaccine to the U.S. government once it receives...

NIH launches clinical trial for COVID-19 antibody treatment
The National Institutes of Health (NIH) has started enrolling volunteers in a phase III randomized, controlled clinical trial to test multiple monoclonal...